Monthly Notifiable Disease Surveillance Report - Oct 2017

Monday 23rd September 2019


Key notifiable disease trends

Chikungunya fever: Two cases of chikungunya fever (1 confirmed and 1 under investigation) were notified in October 2017. After further investigation, one case has since been found to not meet the case criteria. The confirmed case in the 1–4 years age group and had travelled to Fiji during the incubation period.

Cryptosporidiosis: 236 cases of cryptosporidiosis (235 confirmed and 1 under investigation) were notified in October 2017 compared to 202 cases notified in October 2016. The 12-month rate for the period ending 31 October (25.1 cases per 100,000 population) was slightly higher than for the same period in the previous year (21.7 per 100,000). Cases ranged in age from 3 months to 83 years, with the highest numbers of cases in the 1–4 years (65 cases) and 20–29 years (47 cases) age groups. Among the cases for which risk factor information was recorded, 76.7% (102/133) had contact with farm animals, 36.1% (48/133) had attended school, preschool or childcare, 33.6% (39/116) consumed untreated water, 29.9% (32/107) had contact with sick animals, 24.8% (31/125) had consumed food from a food premises and 23.0% (29/126) had contact with faecal matter or vomit during the incubation period. One finalised Cryptosporidium outbreak (5 cases) was created in October.

Leptospirosis: 10 cases of leptospirosis (3 confirmed and 7 under investigation) were notified in October 2017 compared to six cases notified in October 2016. The highest number of cases was reported in the 40–49 years and 50–59 years (3 cases each) age group. Occupation was recorded for 80.0% (8/10) of cases. Of these, seven were engaged in occupation previously identified as high risk exposure to Leptospira species: farmers or farm workers (5 cases) and meat workers (2 cases). One case reported exposure through contact with rats. Two cases did not have any risk factor information recorded.

Meningococcal disease: 14 cases of meningococcal disease (12 confirmed and 2 probable) were notified in October 2017 compared to six cases notified in October 2016 (Figure 1). The highest number of cases were reported from Waitemata (4 cases) and Canterbury (3 cases) DHBs. The cases were in the 1–4 years, 15–19 years, 20–29 years, 40–49 years, 50–59, 60–69 years (2 cases each), 10–14 years, and 70 years and over (1 case each) age groups. Twelve cases were hospitalised and no deaths were reported. Twelve cases laboratory confirmed and the group was determined for 11 cases: group B (8 cases, including 5 NZ B:P1.7-2,4), group W (2 cases) and group Y (1 case).

Mumps: 290 cases of mumps (198 confirmed, 56 probable and 36 under investigation) were notified in October 2017 compared with five cases notified in October 2016 (Figure 2). The 12-month rate for the period ending 31 October was 20.3 cases per 100,000 population. After further investigation two cases were found not to meet the case criteria. The highest numbers of cases were reported from Counties Manukau (115 cases), Auckland (87 cases), and Waitemata (45 cases) DHBs. The highest numbers of cases were in the 20–29 years (119 cases) and 15–19 years (81 cases) age groups. One-hundred and ten cases were recorded as being vaccinated against mumps, of which 93 cases had received two doses of the vaccine and 16 cases had received just one dose. One further cases had been vaccinated, but no dose information was available. Vaccination status was unknown for 124 cases and 35 cases were recorded as non-vaccinated.

Pertussis: 171 cases of pertussis (110 confirmed, 40 probable, 5 suspected, and 16 under investigation) were notified in October 2017 compared to 101 cases in October 2016. The 12-month rate for the period ending 31 October (31.1 cases per 100,000) was higher than fort the same period in the previous year (22.7 per 100,000). Fourteen cases were hospitalised and no deaths were reported. Sixty percent (103/171) of cases were laboratory-confirmed (20 by culture, 70 by PCR, and 13 by culture and PCR). The highest number of cases was reported from Auckland DHB (24 cases), followed by Canterbury (21 cases), Waikato (18 cases) and Northland (17 cases) DHBs. Cases ranged in age from 1 month to 85 years, with 19.3% (33/171) under five years of age (including 18 cases aged less than 1 year). The highest numbers of cases were in the 5–9 years (23 cases), 10–14 years, 40–49 years and 50–59 years (21 cases each) age groups.

Ross River virus infection: One confirmed case of Ross River virus infection was notified in October 2017. The case was in the 40–49 years age group and had travelled to Australia during the incubation period.

Shigellosis: 18 confirmed cases of shigellosis were notified in October 2017 compared with 15 cases notified In October 2016. The 12-month rate for the period ending 31 October (5.0 cases per 100,000 population) was higher than at the same time in the previous year (3.1per 100,000). The highest number of cases was reported from Auckland (6 cases) DHB. The serotype involved was recorded for 94.4% (17/18) of cases: S. sonnei biotype a (6 cases), S. flexneri 2a, S. sonnei biotype g (4 cases each), S. boydii 2, S. boydii 4 and S. boydii 8 (1 case each). Information on overseas travel during the incubation period was recorded for 72.2% (13/18) of cases, of which 61.5% (8/13) of cases recorded overseas travel during this period. Countries/region visited included: Samoa (3 cases), Indonesia (2 cases), China, Morocco, Pakistan, and South East Asia (1 case each). One case reported overseas travel to more than one country. One further case had a prior history of travel.

VTEC/STEC infection: 56 cases of VTEC/STEC infection (46 confirmed and 10 under investigation) were notified in October 2017 compared to 38 cases notified in October 2016. The 12-month rate for the period ending 31 October 2017 (11.2 cases per 100,000 population) was higher than at the same time period in the previous year (9.2 cases per 100,000 population). After further investigation two cases were found not to meet the case criteria. The highest numbers of cases were reported from Southern (16 cases) and Northland (8 cases) DHBs. Cases ranged in age from 7 months to 84 years, with the highest number of cases in the 1–4 years (15 cases). Eight cases were hospitalised. Twenty-six cases have been confirmed by the Enteric Reference Laboratory as being infected with VTEC/STEC, and of these the serotype was identified as Escherichia coli O157:H7 (17 cases) and non-O157 (9 cases). Of the cases for which risk factor information was recorded, 81.1% (30/37) had contact with animals, 32.4% (11/34) had contact with children in nappies, 26.5% (9/34) had recreational contact with water and 16.2% (6/37) had contact with a person with similar symptoms during the incubation period. One interim VTEC/STEC infection outbreak (case numbers yet to be determined) was created in October.

Note: Click on the document links below to open. These documents are in PDF format. You will need to download the free Adobe Acrobat Reader to view them.

Report:

Monthly Notifiable Disease Surveillance Report - Oct 2017

Tables:

Monthly National Totals - October 2017

Monthly DHB Totals - October2017

Monthly Rolling Totals - October 2017

 

DOWNLOADS

Monthly Notifiable Disease Surveillance Report - Oct 2017

Tables:

Monthly National Totals - October 2017

Monthly DHB Totals - October2017

Monthly Rolling Totals - October 2017

Ph: +64 4 914 0700 Fax: +64 4 914 0770 Email: survqueries@esr.cri.nz